The company was researching rare dermatological diseases with no approved treatments, according to its website.
Timber and its subsidiary BioPharmX, a specialty dermatology pharmaceutical company, are now in a “stalking horse” agreement with LEO Pharma, which signed a deal in August to acquire Timber for about $14 million. The stalking horse asset purchase agreement allows LEO Pharma to sell Timber for the acquisition price.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.